Human Insulin

FDA Drug Profile — Novolin 70/30, Novolin N, Novolin R

Drug Details

Generic Name
Human Insulin
Brand Names
Novolin 70/30, Novolin N, Novolin R
Application Number
BLA019991
Sponsor
Novo Nordisk
NDC Codes
8
Dosage Forms
INJECTION, SUSPENSION, INJECTION, SOLUTION
Routes
SUBCUTANEOUS
Active Ingredients
INSULIN HUMAN

Indications and Usage

1 INDICATIONS AND USAGE NOVOLIN 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. Limitations of Use: In NOVOLIN 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. NOVOLIN 70/30 is a mixture of human insulin isophane, an intermediate-acting human insulin, and human insulin, a short-acting human insulin, indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. ( 1 )